Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies

Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

(2015) O. Fernández et al.   NEUROLOGIA

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Brentuximab vedotin

(2014) S. M. Ansell   BLOOD

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

(2014) Raed A Alroughani et al.   BMC Neurology

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

(2014) Kenneth R. Carson et al.   CANCER

Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis

(2014) Carmen Tur et al.   CNS DRUGS

Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab Therapy

(2013) H. Hendel-Chavez et al.   JOURNAL OF VIROLOGY

Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients

(2013) Samantha Jilek et al.   Multiple Sclerosis Journal

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab for the treatment of lymphoproliferative disorders

(2012) Carolyn Owen et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

(2011) Namita Kothary et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Detection of JC virus DNA fragments but not proteins in normal brain tissue

(2008) Georgina Perez-Liz et al.   ANNALS OF NEUROLOGY

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

(2008) F. Zohren et al.   BLOOD

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

(2008) H. Bonig et al.   BLOOD

Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals

(2008) Serena Delbue et al.   JOURNAL OF MEDICAL VIROLOGY

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

(2008) Raija L.P. Lindberg et al.   JOURNAL OF NEUROIMMUNOLOGY

Interferon β1-a and selective anti-5HT2a receptor antagonists inhibit infection of human glial cells by JC virus

(2008) B.A. O’Hara et al.   VIRUS RESEARCH